Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages i37-i45

  Alberici, Federico ^a,b,c   Martorana, Davide ^c   Vaglio, Augusto ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

ANCA; HLA; PTPN22; vasculitis

Indexed keywords

ANCA ASSOCIATED VASCULITIS; ANTIBODY SPECIFICITY; CD4 LYMPHOCYTE COUNT; CTLA 4 GENE; CYTOTOXICITY; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HLA DP1 GENE; HLA DQ GENE; HLA DRB4 GENE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROMOTER REGION; PRTN3 GENE; PTPN22 GENE; REVIEW; SERPINA1 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; AUTOIMMUNITY; GENETICS;

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOIMMUNITY; GENOME-WIDE ASSOCIATION STUDY; HUMANS;

EID: 84926630456     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu386     Document Type: Review

References (81)

1. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculit-ides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192
2. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44
3. Mahr A, Katsahian S, Varet H et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2013; 72: 1003-1010
4. Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculit-ides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222-227
5. Sable-Fourtassou R, Cohen P, Mahr A et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143: 632-638
6. Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367: 214-223
7. Xie G, Roshandel D, Sherva R et al. Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1∗04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum 2013; 65: 2457-2468
8. Wieczorek S, Hoffjan S, Chan A et al. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. Genes Immun 2009; 10: 591-595
9. Carr EJ, Niederer HA, Williams J et al. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Med Genet 2009; 10: 121
10. Wieczorek S, Holle JU, Bremer JP et al. Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener's granulomatosis and Churg-Strauss syndrome. Rheumatology (Oxford) 2010; 49: 907-914
11. Tsuchiya N, Kobayashi S, Hashimoto H et al. Association of HLA-DRB1∗0901-DQB1∗0303 haplotype with microscopic polyangiitis in Japanese. Genes Immun 2006; 7: 81-84
12. Wieczorek S, Hellmich B, Gross WL et al. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum 2008; 58: 329-330
13. Vaglio A, Martorana D, Maggiore U et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007; 56: 3159-3166
14. Wieczorek S, Hellmich B, Arning L et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum 2008; 58: 1839-1848
15. Carr EJ, Clatworthy MR, Lowe CE et al. Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis. BMC Med Genet 2009; 10: 22
16. Wieczorek S, Holle JU, Muller S et al. A functionally relevant IRF5 haplotype is associated with reduced risk to Wegener's granulomatosis. J Mol Med (Berl) 2010; 88: 413-421
17. Miyashita R, Tsuchiya N, Yabe T et al. Association of killer cell immuno-globulin-like receptor genotypes with microscopic polyangiitis. Arthritis Rheum 2006; 54: 992-997
18. Mamegano K, Kuroki K, Miyashita R et al. Association of LILRA2 (ILT1, LIR7) splice site polymorphism with systemic lupus erythematosus and microscopic polyangiitis. Genes Immun 2008; 9: 214-223
19. Jagiello P, Aries P, Arning L et al. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005; 52: 4039-4043
20. Martorana D, Maritati F, Malerba G et al. PTPN22 R620W polymorphism in the ANCA-associated vasculitides. Rheumatology (Oxford) 2012; 51: 805-812
21. Husmann CA, Holle JU, Moosig F et al. Genetics of toll like receptor 9 in ANCA associated vasculitides. Ann Rheum Dis 2014; 73: 890-896
22. Willcocks LC, Lyons PA, Clatworthy MR et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med 2008; 205:1573-1582
23. Fanciulli M, Norsworthy PJ, Petretto E et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 2007; 39: 721-723
24. Raychaudhuri S, Sandor C, Stahl EA et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44: 291-296
25. Baschal EE, Aly TA, Babu SR et al. HLA-DPB1∗0402 protects against type 1A diabetes autoimmunity in the highest risk DR3-DQB1∗0201/DR4-DQB1∗0302 DAISY population. Diabetes 2007; 56: 2405-2409
26. Taneja V, Behrens M, Basal E et al. Delineating the role of the HLA-DR4 'shared epitope' in susceptibility versus resistance to develop arthritis. J Immunol 2008; 181: 2869-2877
27. Jagiello P, Gencik M, Arning L et al. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 2004; 114: 468-477
28. Heckmann M, Holle JU, Arning L et al. The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. Ann Rheum Dis 2008; 67: 972-979
29. Stassen PM, Cohen-Tervaert JW, Lems SP et al. HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. Rheumatology (Oxford) 2009; 48: 622-625
30. Cao Y, Schmitz JL, Yang J et al. DRB1∗15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol 2011; 22: 1161-1167
31. Luo H, Chen M, Yang R et al. The association of HLA-DRB1 alleles with antineutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese patients. Hum Immunol 2011; 72: 422-425
32. Cotch MF, Fauci AS, Hoffman GS. HLA typing in patients with Wegener granulomatosis. Ann Intern Med 1995; 122: 635
33. Papiha SS, Murty GE, Ad'Hia A et al. Association of Wegener's granulo-matosis with HLA antigens and other genetic markers. Ann Rheum Dis 1992; 51: 246-248
34. Spencer SJ, Burns A, Gaskin G et al. HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int 1992; 41: 1059-1063
35. Witko-Sarsat V, Cramer EM, Hieblot C et al. Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules. Blood 1999; 94: 2487-2496
36. Campbell EJ, Campbell MA, Owen CA. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J Immunol 2000; 165: 3366-3374
37. Yang JJ, Tuttle RH, Hogan SL et al. Target antigens for anti-neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils. Clin Exp Immunol 2000; 121: 165-172
38. Witko-Sarsat V, Lesavre P, Lopez S et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999; 10: 1224-1233
39. Schreiber A, Busjahn A, Luft FC et al. Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 2003; 14: 68-75
40. Gencik M, Meller S, Borgmann S et al. Proteinase 3 gene polymorphisms and Wegener's granulomatosis. Kidney Int 2000; 58: 2473-2477
41. Elzouki AN, Segelmark M, Wieslander J et al. Strong link between the alpha 1-antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med 1994; 236: 543-548
42. Baslund B, Szpirt W, Eriksson S et al. Complexes between proteinase 3, alpha 1-antitrypsin and proteinase 3 anti-neutrophil cytoplasm autoantibodies: a comparison between alpha 1-antitrypsin PiZ allele carriers and non-carriers with Wegener's granulomatosis. Eur J Clin Invest 1996; 26: 786-792
43. Borgmann S, Endisch G, Urban S et al. A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis. Clin Immunol 2001; 98: 244-248
44. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365: 2225-2236
45. Segelmark M, Elzouki AN, Wieslander J et al. The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vascu-litis. Kidney Int 1995; 48: 844-850
46. Mahr AD, Edberg JC, Stone JH et al. Alpha(1)-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis Rheum 2010; 62: 3760-3767
47. Alberici F, Jayne DR. Impact of rituximab trials on the treatment of ANCA-associated vasculitis. Nephrol Dial Transplant 2014; 29: 1151-1159
48. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 147-153
49. Abdulahad WH, De Souza AW, Kallenberg CG. L3. Are mononuclear cells predominant actors of endothelial damage in vasculitis? Presse Med 2013; 42(4 Pt 2): 499-503
50. Maine CJ, Hamilton-Williams EE, Cheung J et al. PTPN22 alters the development of regulatory T cells in the thymus. J Immunol 2012; 188: 5267-5275
51. Bayley R, Kite KA, McGettrick HM et al. The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 2014; doi: 10.1136/annrheumdis-2013-204796
52. Noel PJ, Boise LH, Green JM et al. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996; 157: 636-642
53. Langford CA, Monach PA, Specks U et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2014; 73: 1376-1379
54. Giscombe R, Wang X, Huang D et al. Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener's gran-ulomatosis. J Rheumatol 2002; 29: 950-953
55. Slot MC, Sokolowska MG, Savelkouls KG et al. Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis. Clin Immunol 2008; 128: 39-45
56. Kamesh L, Heward JM, Williams JM et al. CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis. Rheumatology (Oxford) 2009; 48: 1502-1505
57. Muzes G, Sipos F. Relation of immune semaphorin/plexin signaling to carcinogenesis. Eur J Cancer Prev 2014; 23: 469-476
58. Wieczorek S, Holle JU, Cohen Tervaert JW et al. The SEM6A6 locus is not associated with granulomatosis with polyangiitis or other forms of antineu-trophil cytoplasmic antibody-associated vasculitides in Europeans: comment on the article by Xie et al. Arthritis Rheumatol 2014; 66: 1400-1401
59. Murakozy G, Gaede KI, Ruprecht B et al. Gene polymorphisms of immu-noregulatory cytokines and angiotensin-converting enzyme in Wegener's granulomatosis. J Mol Med (Berl) 2001; 79: 665-670
60. Bartfai Z, Gaede KI, Russell KA et al. Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. Clin Immunol 2003; 109: 330-337
61. Caruso C, Candore G, Cigna D et al. Biological significance of soluble IL-2 receptor. Mediators Inflamm 1993; 2: 3-21
62. Fontenot JD, Rasmussen JP, Gavin MA et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151
63. Lakshmikanth T, Burke S, Ali TH et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest2009; 119: 1251-1263
64. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10: 328-343
65. Dijstelbloem HM, Scheepers RH, Oost WW et al. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum 1999; 42: 1823-1827
66. Tse WY, Abadeh S, McTiernan A et al. No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol 1999; 117: 198-205
67. Niederer HA, Willcocks LC, Rayner TF et al. Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet 2010; 19: 3282-3294
68. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel inter-feron regulatory factor, IRF-5, results in the induction of distinct inter-feron alpha genes. J Biol Chem 2001; 276: 23382-23390
69. Kawasaki A, Inoue N, Ajimi C et al. Association of IRF5 polymorphism with MPO-ANCA-positive vasculitis in a Japanese population. Genes Immun 2013; 14: 527-529
70. Popa ER, Stegeman CA, Abdulahad WH et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46: 1029-1033
71. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol 2006; 6: 447-456
72. Zhou XJ, Cheng FJ, Lv JC et al. Higher DEFB4 genomic copy number in SLE and ANCA-associated small vasculitis. Rheumatology (Oxford) 2012; 51: 992-995
73. Persson U, Truedsson L, Westman KW et al. C3 and C4 allotypes in anti-neutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis. Clin Exp Immunol 1999; 116: 379-382
74. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008; 67: 1322-1327
75. Franssen CF, Stegeman CA, Kallenberg CG et al. Antiproteinase 3-and anti-myeloperoxidase-associated vasculitis. Kidney Int 2000; 57: 2195-2206
76. de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013; 8: 1709-1717
77. Quintana LF, Perez NS, De Sousa E et al. ANCA serotype and histopatho-logical classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2014; 29: 1764-1769
78. Franssen C, Gans R, Kallenberg C et al. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 1998; 244: 209-216
79. Arulkumaran N, Periselneris N, Gaskin G et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 2011; 50: 2035-2043
80. Lionaki S, Blyth ER, Hogan SL et al. Classification of antineutrophil cyto-plasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012; 64: 3452-3462
81. Suppiah R, Judge A, Batra R et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res 2011; 63: 588-596